Interleukin-10 (IL-10) is a cytokine produced primarily by monocytes and, to a lesser extent, by lymphocytes [1] . This cytokine has an effect on immunoregulation and inflammation [2, 3] . It downregulates the expression of Th1 cytokines, major histocompatibility complex (MHC) class II antigens, and co-stimulatory molecules on macrophages [4, 5] . It also has the ability to inhibit synthesis of pro-inflammatory cytokines such as interferon γ(IFN γ), IL-2, IL-3, tumor necrosis factor (TNFα) and granulocyte-macrophage colony stimulating factor (GM-CSF) produced by macrophages and T helper type 1 cells [2, 6] . IL-10 also displays potent ability to suppress antigen presentation by antigen presenting cells [7] .
Our aim is to increase the effective utility of donated blood products. Therefore, based on the information from the literature cited above, we analyzed serum containing high levels of IL-10 (arbitrarily designated "IL-10 serum"), derived from normal healthy blood donors, for its ability to inhibit the cytotoxic activity of a number of alloreactive, and one Epstein-Barr virus (EBV)-specific, cytotoxic T cell clones. In this study we have specifically focused on the granzyme B [8, 9] and perforin [10, 11] release profiles from these clones. In addition, we have tested whether anti-IL10 IgG containing serum (arbitrarily designated "anti-IL-10 IgG serum") derived from normal healthy blood donors can neutralize the inhibitory effects of IL-10 serum.
Our results indicate that, during a 4-hour cytotoxic assay, IL-10 serum inhibited cytotoxic activity against target cells and granzyme B release from both alloreactive T cell clones and an EBV-specific cytotoxic T cell clone. Furthermore, in the presence of anti-IL10 IgG serum, these inhibitory effects were diminished. In contrast, perforin, a serine protease that is released from cytotoxic T cells concomitantly with granzyme B, was not inhibited by the addition of IL-10 serum.
RESULTS

An inhibitory effect by IL-10 serum
In the presence of IL-10 serum, percent specific lysis of target phytohemagglutinin (PHA)-blasted target peripheral blood mononuclear cells (PBMCs) was significantly inhibited in two CD4 + alloreactive T cell clones (arbitrarily designated "clone 1" and "clone 2") (Figs. 1a and b) and in one CD8 + alloreactive T cell clone (arbitrarily designated "clone 3") ( Fig. 1c) . In addition, the amount of granzyme B released into the culture supernatant was notably reduced in the presence of IL-10 serum compared to that of control serum for both CD4 + and CD8 + clones (Figs. 1a-c) .
Depletion of IL-10 from IL-10 serum
When the IL-10 present in IL-10 serum was depleted using anti-IL-10 monoclonal antibody (mAb)-conjugated protein G-sepharose 4B beads, the inhibitory effect on cytotoxic activity and granzyme B release from alloreactive cytotoxic T cell clones was diminished (Fig. 2) .
Neutralizing activity of anti-IL-10 IgG serum
Furthermore, by mixing anti-IL-10 IgG serum in the culture, both the cytotoxic activity and granzyme B release from alloreactive cytotoxic T cell clones was recovered (Figs. 3a and b). Anti-IL-10 IgG serum did not effect either alloreactive or an EBV-specific cytotoxic T cell clone (data not shown).
Exposure to IL-10 serum has a continued effect on alloreactive cytotoxic T cell clones
To determine the recovery of T cell clones from suppression by IL-10 serum, the clones were mixed with a 10% volume of control or IL-10 serum followed by incubation at 37℃ for 4 hours. After washing three times with RPMI 1640 medium, clones were cultured in fresh medium [RPMI 1640 + 10% fetal calf serum (FCS) + 50 u/ml recombinant IL-2 (rIL-2)] for 24 hours at 37℃, and then subjected to a cytotoxic assay.
Cytotoxic activity (Figs. 4a and b) and granzyme B release (Figs. 4c and d) was still inhibited compared to the control serum.
Activity of an EBV-specific cytotoxic T cell clone
An EBV-specific cytotoxic T cell clone (arbitrarily designated as "clone 125") showed cytotoxic activity against an autologous B lymphoblastoid cell line (B-LCL), three allogeneic B-LCLs (arbitrarily designated as "Allo-1 B-LCL", "Allo-2 B-LCL" and "Allo-3" B-LCL) and Raji cells [12] , all of which express abundant levels of EBV protein on the cell surface (Fig. 5) . The clone showed no activity against K562 cells that are used as a target for natural killer cells (Fig. 5) . These results suggest that clone 125 is EBV-specific but is not alloreactive because Allo-1, Allo-2 and Allo-3 B-LCL do not share the same MHC antigens. Clone 125 is thought to recognize EBV antigens expressed on the cell surface, and therefore is not restricted by MHC antigens.
Moreover, clone 125 is considered to have no natural killer activity, since it has almost no cytotoxic activity against K562 cells.
The effect of IL-10 serum and anti-IL10 IgG free serum on an EBV-specific cytotoxic T cell clone Cytotoxic activity and granzyme B release from clone 125 against autologous (Fig. 6a) and allogeneic B-LCLs (Fig. 6b) was also inhibited in the presence of IL-10 serum. However, IL-10 depletion from IL-10 serum was effective in recovering this activity (Fig. 7a) . It was also recovered by the addition of anti-IL-10 IgG serum with IL-10 serum (Fig. 7a) . This neutralizing activity was diminished by the addition of anti-IL-10
IgG free serum (Fig. 7b) .
Perforin release
In the same experiment, in contrast to granzyme B, perforin release was not inhibited by Granzyme B is a cysteine protease found in the cytoplasmic granules of cytotoxic T cells and natural killer cells. Granzyme B is required for the induction of target cell lysis that occurs as part of cell mediated immune responses, and it can activate apoptosis in target cells [8, 9, [25] [26] [27] . In this study, we found that IL-10 serum treatment inhibited granzyme B release at an early stage and effectively eliminated the cytotoxic activity of cytotoxic T cell clones. The mechanism of how this occurs is now under investigation.
Perforin is a serine protease that is released from cytotoxic T cells, and is one of the main mediators of cell killing [10, 11, 28] . However, in contrast to granzyme B, we found that its release from cytotoxic T cell clones was not inhibited by IL-10. One possible explanation for this is that IL-10 has different effects on the release mechanisms of perforin and granzyme B. The precise mechanism of IL-10 action on granule release is now under consideration.
METHODS
Serum preparation. IL-10 concentration in the serum was determined using an enzyme-linked immunosorbent assay (ELISA) kit (Pierce Biotechnology, Inc., Rockford, IL, USA). The IL-10 concentrations in sera obtained from 280 normal healthy blood donors were tested. One serum, in which IL-10 concentration was found to be over four standard deviations from the mean (IL-10 concentration = 29.5 ng/ml), was used in this study and designated "IL-10 serum". Anti-IL-10 IgG levels in the sera were also measured using ELISA. In brief, 100 μg/ml recombinant IL-10 (rIL-10: BioVission
Research Products, Mountain View, CA, USA) was coated onto a 96-well ELISA plate (Corning Incorporated, Corning, NY, USA) and incubated with 10-fold diluted sera in TTBS (20 mM Tris, 500 mM NaCl, 0.05% Tween-20, pH 7.5) followed by incubation with horseradish peroxidase-conjugated anti-human IgG rabbit F(ab') 2 (DakoCytomation A/S, Glostrup, Denmark). This was followed by incubation with the substrate 3, 3', 5, 5'-tetramehylbenzidine (TMB: DakoCytomation A/S). The reaction was stopped by the addition of H 2 SO 4 and absorbance at 450 nm was measured. One serum in which absorbance levels were over five standard deviations from the mean was used in this study and designated "anti-IL-10 IgG serum". Serum derived from a normal healthy individual that was free of both IL-10 and anti-IL-10 IgG was used as a control.
Establishment of alloreactive cytotoxic T cell clones.
Alloreactive cytotoxic T cell clones were established by the co-culture of PBMCs obtained from two unrelated healthy individuals followed by the limiting dilution method as described previously Establishment of an EBV-specific cytotoxic T cell clone. Semi-purified T cells were prepared from PBMCs derived from a healthy individual, using a nylon-wool column as described above. These cells were used as responder cells. Autologous PBMCs were 25
Gy X-ray irradiated and mixed with EBV. These cells were used as stimulators.
Responder and stimulator cells were co-cultured for 3 days at 37℃ in RPMI 1640 medium supplemented with 10% FCS (HyClone). Cloning was performed using the limiting dilution method. One CD4 + T cell clone (arbitrarily designated as "clone 125") was obtained that displayed cytotoxic activity against autologous EBV-transformed B-LCL but not autologous PHA-blasted PBMCs. This clone was used as the EBV-specific cytotoxic T cell clone in this study. Clone 125 was maintained in RPMI 1640 medium supplemented with 10% FCS (HyClone) and 50 u/ml of rIL-2 (Genzyme Diagnostics).
Statistical analysis. Means and standard deviations (SDs) were calculated and data analyzed using a Student's t-test. Statistical significance was defined as p < 0.05. 
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